导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -11.90% | 3876/4773 |
| 近一周 | -2.07% | 3341/5465 |
| 近一月 | -1.76% | 1277/5421 |
| 近一季 | -0.66% | 1108/5231 |
| 近半年 | -8.86% | 3565/4920 |
| 近一年 | -16.80% | 3843/4394 |
| 近两年 | 26.65% | 2427/2954 |
| 近三年 | 25.61% | 1282/2253 |
| 成立以来 | -5.36% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-8.24% 4269/4961 |
-11.18% 4247/5312 |
- - |
- - |
| 2025 | 20.73% 2099/4813 |
16.08% 145/3635 |
1.47% 2315/4076 |
10.44% 3291/4524 |
-7.20% 3775/4813 |
| 2024 | 33.11% 78/3463 |
1.91% 847/2808 |
12.71% 19/3014 |
15.98% 1575/3129 |
-0.07% 1308/3463 |
| 2023 | -14.44% 1603/2656 |
-0.65% 1816/2280 |
-1.64% 510/2385 |
-6.53% 1483/2515 |
-6.32% 1719/2655 |
| 2022 | -7.24% 140/2207 |
-9.76% 342/1919 |
8.41% 367/2016 |
-15.37% 1277/2113 |
12.04% 129/2208 |
| 2021 | -18.67% 1171/1822 |
3.43% 177/1255 |
-2.33% 1200/1330 |
-13.80% 1358/1466 |
-6.59% 1542/1822 |
| 2020 | -6.79% 979/1250 |
-11.41% 839/1028 |
2.42% 972/1067 |
-6.28% 1119/1164 |
9.62% 628/1184 |
| 2019 | 13.23% 708/1092 |
8.89% 727/739 |
-0.53% 264/788 |
-3.15% 728/850 |
7.94% 378/918 |
| 2018 | - - |
- - |
-1.95% 61/631 |
4.99% 65/660 |
-8.12% 81/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 南方恒生国企ETF联接A VS. 长安沪深300非周期A(740101) |